Related Experiment Video
Updated: Apr 25, 2026
A Mouse Model of Single and Repetitive Mild Traumatic Brain Injury
Published on: June 20, 2017
A study on the mechanism by which MDMA protects against dopaminergic dysfunction after minimal traumatic brain injury
S Edut1, V Rubovitch, M Rehavi
1Department of Anatomy and Anthropology, Sackler Faculty of Medicine, Tel Aviv University, 69978, Tel Aviv, Israel, eshaha12@campus.haifa.ac.il.
Abstract:
Driving under methylenedioxymethamphetamine (MDMA) influence increases the risk of being involved in a car accident, which in turn can lead to traumatic brain injury. The behavioral deficits after traumatic brain injury (TBI) are closely connected to dopamine pathway dysregulation. We have previously demonstrated in mice that low MDMA doses prior to mTBI can lead to better performances in cognitive tests. The purpose of this study was to assess in mice the changes in the dopamine system that occurs after both MDMA and minimal traumatic brain injury (mTBI). Experimental mTBI was induced using a concussive head trauma device. One hour before injury, animals were subjected to MDMA. Administration of MDMA before injury normalized the alterations in tyrosine hydroxylase (TH) levels that were observed in mTBI mice. This normalization was also able to lower the elevated dopamine receptor type 2 (D2) levels observed after mTBI. Brain-derived neurotrophic factor (BDNF) levels did not change following injury alone, but in mice subjected to MDMA and mTBI, significant elevations were observed. In the behavioral tests, haloperidol reversed the neuroprotection seen when MDMA was administered prior to injury. Altered catecholamine synthesis and high D2 receptor levels contribute to cognitive dysfunction, and strategies to normalize TH signaling and D2 levels may provide relief for the deficits observed after injury. Pretreatment with MDMA kept TH and D2 receptor at normal levels, allowing regular dopamine system activity. While the beneficial effect we observe was due to a dangerous recreational drug, understanding the alterations in dopamine and the mechanism of dysfunction at a cellular level can lead to legal therapies and potential candidates for clinical use.
Insights
Pre-treating mice with methylenedioxymethamphetamine (MDMA) before minimal traumatic brain injury (mTBI) normalized dopamine system activity. This suggests potential therapeutic strategies for cognitive deficits following brain injury.
Area of Science:
- Neuroscience
- Pharmacology
- Traumatology
Background:
- Traumatic brain injury (TBI) can cause behavioral deficits linked to dopamine pathway dysregulation.
- Methylenedioxymethamphetamine (MDMA) use increases accident risk, potentially leading to TBI.
- Previous studies suggest low-dose MDMA pre-treatment may improve cognitive function post-mTBI.
Purpose of the Study:
- To investigate the effects of MDMA and minimal traumatic brain injury (mTBI) on the dopamine system in mice.
- To determine if MDMA pre-treatment can mitigate mTBI-induced changes in dopamine pathways.
Main Methods:
- Mice received MDMA one hour before experimental mTBI induction.
- Tyrosine hydroxylase (TH), dopamine receptor type 2 (D2), and brain-derived neurotrophic factor (BDNF) levels were measured.
- Behavioral tests were conducted, with haloperidol used to assess neuroprotection.
Main Results:
- MDMA pre-treatment normalized mTBI-induced alterations in TH levels.
- Elevated D2 receptor levels post-mTBI were reduced by MDMA pre-treatment.
- MDMA and mTBI significantly increased BDNF levels.
- Haloperidol reversed the cognitive benefits of MDMA pre-treatment.
Conclusions:
- MDMA pre-treatment normalizes dopamine system activity (TH and D2 levels) after mTBI in mice.
- Understanding these dopamine pathway alterations could lead to novel therapeutic strategies for TBI-related cognitive dysfunction.
- While MDMA itself is not a viable therapy, its mechanism offers insights for developing legal treatments.
